Orvepitant
- Generic Name
- Orvepitant
- Drug Type
- Small Molecule
- Chemical Formula
- C31H35F7N4O2
- CAS Number
- 579475-18-6
- Unique Ingredient Identifier
- IIU6V0W3JD
- Background
Orvepitant has been used in trials studying the treatment of Depressive Disorder, Depressive Disorder, Major, Post-Traumatic Stress Disorder, and Posttraumatic Stress Disorder (PTSD).
Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
- Conditions
- CoughIdiopathic Pulmonary Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05185089
- Locations
- 🇺🇸
PulmonIx, LLC, Greensboro, North Carolina, United States
🇺🇸Baylor University, Dallas, Texas, United States
🇺🇸Jadestone Clinical Research, LLC, Silver Spring, Maryland, United States
A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers
- Conditions
- Pharmacokinetic Study in Healthy Male Volunteers
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03535662
- Locations
- 🇬🇧
Parexel Epcu, Harrow, Middlesex, United Kingdom
A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Registration Number
- NCT03464526
A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough
- Conditions
- Chronic Refractory Cough
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Nerre Therapeutics Ltd.
- Target Recruit Count
- 315
- Registration Number
- NCT02993822
- Locations
- 🇺🇸
Study Site 22, Dallas, Texas, United States
🇺🇸Study Site 43, Los Angeles, California, United States
🇺🇸Study Site 10, Houston, Texas, United States
Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 132
- Registration Number
- NCT01000493
- Locations
- 🇺🇸
GSK Investigational Site, Middleton, Wisconsin, United States
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 343
- Registration Number
- NCT00880048
- Locations
- 🇨🇦
GSK Investigational Site, Gatineau, Quebec, Canada
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 328
- Registration Number
- NCT00880399
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Food and Relative Bioavailability Study
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00843011
- Locations
- 🇮🇹
GSK Investigational Site, Verona, Veneto, Italy
GW823296 Repeat Dose Study In Healthy Male And Female Subjects
- Conditions
- Healthy Subjects
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00675116
- Locations
- 🇦🇺
GSK Investigational Site, Adelaide, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.